Team:Lethbridge/safety

From 2014.igem.org

(Difference between revisions)
 
(146 intermediate revisions not shown)
Line 3: Line 3:
<html>
<html>
<style>
<style>
 +
p.ex5{
 +
    margin-right: 30.0pt;
 +
    margin-left: 30.0pt;
 +
    text-align: left;
 +
 +
}
 +
p.ex3
 +
{
 +
    margin-right: 54.0pt;
 +
    margin-left: 18.0pt;
 +
}
 +
 +
p.ex2 {
 +
    text-align:left;
 +
    margin-left: 18.0pt;
 +
}
 +
p.ex {
 +
    margin-right: 30.0pt;
 +
    margin-left: 30.0pt;
 +
}
div
div
{
{
text-align:justify;
text-align:justify;
-
text-justify:inter-word;
 
}
}
</style>
</style>
-
<!-- <center>
+
<br>
-
<image src="https://static.igem.org/mediawiki/2013/e/ee/Pseudoknot_no_induced_frameshift.gif" height="400px"  width="450px"/>
+
<center><image src="https://static.igem.org/mediawiki/2013/7/74/Safety_uofl_2013.png" width="600px" height="300px"/></center>
-
<image src="https://static.igem.org/mediawiki/2013/b/b2/Pseudoknot_inducing_frameshift.gif"; height="400px"; width="450px"/></center>
+
-
<center><table><tr><td><b>No Frameshifting with Continued Translation &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Frameshifting into -1 Frame</b></td></tr></table></center>-->
+
</html>  
</html>  
-
 
<BLOCKQUOTE>
<BLOCKQUOTE>
-
=<font color="black">Safety NEED NEW SAFETY FORM!=
+
=<font color="black">Safety=
-
 
+
<html>
<html>
-
<body>
+
<font color="black">
-
<h3><b>Basic Safety Questions for Lethbridge iGEM 2013</b></h3>
+
<BLOCKQUOTE>
-
<ol><li>a. Please describe the chassis organism(s) you will be using for this project. If you will be using more than one chassis organism, provide information on each of them:
+
-
<ul><li>Species: Escherichia coli </li>
+
-
<li>Strain no/name: DHα and BL21 DE3 </li>
+
-
<li>Risk Group: 1</li>
+
-
<li>Risk group source link: www.cmu.edu/osp/regulatory-compliance/rDNA_Documents/</li>
+
-
<li>Disease risk to humans? If so, which disease? Very low risk, not associated with causing disease in humans</li></ul>
+
-
<li> Highest Risk Group listed: 1</li>
+
-
 
+
-
<li> List and describe all new or modified coding regions you will be using in your project. (If you use parts from the 2013 iGEM Distribution without modifying them, you do not need to list those parts.)
+
-
<ol><li> Part number: BBa_K1210000
+
-
<ul><li>Where did you get the physical DNA for this part (which lab, synthesis company, etc) : Synthesized, GENEWIZ</li>
+
-
<li>What species does this part originally come from?: Virus</li>
+
-
<li>What is the Risk Group of the species?: 2</li>
+
-
<li>What is the function of this part, in its parent species?: Programmed -1 ribosomal frameshifting</li></li></ul>
+
-
 
+
-
<li>Part number: BBa_K1210001
+
-
<ul><li>Where did you get the physical DNA for this part (which lab, synthesis company, etc) : Synthesized, GENEWIZ</li>
+
-
<li>What species does this part originally come from?: IBV- Infectious bronchitis virus</li>
+
-
<li>What is the Risk Group of the species?: 2</li>
+
-
<li>What is the function of this part, in its parent species?: Programmed -1 ribosomal frameshifting</li></li></ul></ol>
+
-
 
+
-
<li> Do the biological materials used in your lab work pose any of the following risks? Please describe.
+
-
<ul><li>a. Risks to the safety and health of team members or others working in the lab?
+
-
<p>There is very minimal risk to safety as we only work with laboratory strains of Escherichia coli, and all team members have previously undergone laboratory safety training. </p></li>
+
-
<li>b. Risks to the safety and health of the general public, if released by design or by accident?
+
-
<p>None of the parts that we have made raise any safety issues.</p></li>
+
-
<li>c. Risks to the environment, if released by design or by accident?
+
-
<p>There are no direct risks to the environment if the parts are released by design or by accident. The organisms containing these parts are not currently designed for environmental applications. Therefore, risk of environmental contamination is very low. </p></li>
+
-
<li>d. Risks to security through malicious misuse by individuals, groups, or countries?
+
-
<p>Our project only poses safety issues if it was to be used to aid in the expression of dangerous sequences making harmful proteins. However, we intend to create software to help genes synthesis companies detect harmful sequences hidden in another frame, preventing the synthesis of dangerous sequences. </p></li></ul></li>
+
-
 
+
-
<li> If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise? (Consider the different categories of risks that are listed in parts a-d of the previous question.) Also, what risks might arise if the knowledge you generate or the methods you develop became widely available? (Note: This is meant to be a somewhat open-ended discussion question.)
+
-
<p>The parts do not cause any harm for the lab worker, public, or the environment. If individuals make use of the frameshifting parts, with the intent of hiding dangerous sequences, synthesis companies may have to modify or develop new screening methods for detecting these dangerous sequences.</p></li>
+
-
<li> Does your project include any design features to address safety risks? (For example: kill switches, auxotrophic chassis, etc.) Note that including such features is not mandatory to participate in iGEM, but many groups choose to include them.
+
-
<p>Our parts do not include any design features to address safety risks. However, we are creating software which will help gene synthesis companies prevent the misuse of our parts for malicious intent. </p></li>
+
-
<li> What safety training have you received (or plan to receive in the future)? Provide a brief description, and a link to your institution’s safety training requirements, if available.
+
-
<p>All iGEM team members have been fully trained in WHMIS as well as an introduction to biosafety basics. http://www.uleth.ca/hum/riskandsafetyservices/pages/Laboratory%20Forms<p></li>
+
-
<li> Under what biosafety provisions will / do you work?
+
-
<ul><li>a. Please provide a link to your institution biosafety guidelines
+
-
<p>http://www.uleth.ca/hum/riskandsafetyservices/</p></li>
+
-
<li>b. Does your institution have an Institutional Biosafety Committee, or an equivalent group? If yes, have you discussed your project with them? Describe any concerns they raised with your project, and any changes you made to your project plan based on their review.
+
-
<p>The University of Lethbridge Risk and Safety Services department has appointed a committee for biosafety. This committee ensures that biological materials are used safely on campus. We have discussed our project with them and they forsee no problems with the Lethbridge 2013 iGEM project. </p></li>
+
-
<li>c. Does your country have national biosafety regulations or guidelines? If so, please provide a link to these regulations or guidelines if possible.
+
-
<p>Yes, http://canadianbiosafetystandards.collaboration.gc.ca/</p></li>
+
-
<li>d. According to the WHO Biosafety Manual, what is the BioSafety Level rating of your lab? (Check the summary table on page 3, and the fuller description that starts on page 9.) If your lab does not fit neatly into category 1, 2, 3, or 4, please describe its safety features [see 2013.igem.org/Safety for help].
+
-
<p>BSL1, we are using a RNA sequence that is from a risk group 2 organism, however, we do not require the use of the actual organism to utilize this element. </p></li>
+
-
<li>e. What is the Risk Group of your chassis organism(s), as you stated in question 1? If it does not match the BSL rating of your laboratory, please explain what additional safety measures you are taking.
+
-
<p>Risk Group 1</p></li></ol>
+
-
 
+
-
<h3><b>Safety Form 2 Questions for Lethbridge iGEM 2013</b></h3>
+
-
<ol><li>Organism name and strain name or number: Infectious bronchitis virus</li>
+
-
<li>Organism Risk Group: Group 2</li>
+
-
<li>If you are using this organism as a chassis, write "chassis". If you are using a genetic part from
+
-
the organism, give the name of the part and a brief description of what it does and why you are
+
-
using it.
+
-
<p>BBa_K120001: includes the sequence for a pseudoknot secondary structural RNA element that can cause programmed -1 frameshifting during translation. We plan to characterize the frameshifting frequency of this pseudoknot and create a library of frameshifting elements.</p>
+
-
 
+
-
<p>BBa_K120000: includes reporter genes upstream and downstream of the pseudoknot, as a construct for testing the frameshift frequency.</p>
+
-
</li>
+
-
<li>How did you physically acquire the organism or part?
+
-
<p>The part was synthesized by GENEWIZ.</p></li>
+
-
 
+
-
<li>What potential safety/health risks to team members, other people at your institution, or the
+
-
general public could arise from your use of this organism/part?
+
-
<p>The part itself is innocuous and not infectious. Since it is just a short sequence of DNA that, when transcribed into RNA, folds into a specific secondary structure, it does not pose a safety threat to our team members, the university, or the general public.</p></li>
+
-
 
+
-
<li>What measures do you intend to take to ensure that your project is safe for team members,
+
-
other people at your institution, and the general public?
+
-
<p>Since the part itself does not pose a safety threat, standard laboratory safety procedures will be followed, including ensuring that the part or the chassis containing the part does not leave the laboratory space. Proper personal protective equipment will be worn at all times when working with the part and all team members are fully trained in WHMIS and biosafety before being allowed to work in the laboratory.</p></li>
+
-
 
+
-
<li> If you are using only a part from the organism, and you believe the part by itself is not
+
-
dangerous, explain why you believe it is not dangerous.
+
-
<p>Use of the part does not require handling of the virus from which it comes. Therefore, the part itself is not dangerous. Pseudoknots are common RNA elements found in organisms besides viruses, and are not dangerous outside of the context of their host.</p></li>
+
-
<li>Why do you need to use this organism/part? Is there an organism/part from a less dangerous
+
<p>1.<strong> Your Training</strong></p>
-
Risk Group that would accomplish the same purpose?
+
-
<p>We use standard E. coli strains as our chassis for the expression of our constructs. The pseudoknot from infectious bronchitis virus (IBV) has been shown to cause frameshifting in E. coli cells. Therefore, the sequence of the IBV pseudoknot was used. Most pseudoknot sequences that have been characterized for frameshifting activity originate from viruses, so the pseudoknot sequence could not be retrieved from a Risk Level 1 organism.</p></li>
+
-
<li>Is the organism/part listed under the Australia Group guidelines, or otherwise restricted for
+
-
transport? If so, how will your team ship this part to iGEM and the Jamborees?
+
-
<p>The organism that the part originates from is not listed under the Australia Group guidelines, and therefore no additional measures are needed for transport of the BioBrick part.</p></li>
+
-
<li>Please describe the BioSafety Level of the lab in which the team works, or description of
+
<p>a) &nbsp;Have your team members received any safety training yet?<br /></p>
-
safety features of lab (Refer to Basic Safety form, question 8. d.). If you are using organisms with
+
<p class="ex">Yes, we have already received safety training.</p>
-
a BSL level greater than you lab, please explain any additional safety precautions you are taking.
+
-
<p>The lab in which the team works is rated as a BioSafety Level 1 laboratory. Prior to starting lab work, all members must complete WHMIS and Biosafety Training. Since use of the part does not require handling of the Risk Level 2 organism that it comes from, no additional safety precautions are necessary.</p></li></ul>
+
 +
<p class=ex4>b) &nbsp;Please briefly describe the topics that you learned about (or will learn about) in your safety training.<br /></p>
 +
<p class="ex">All University of Lethbridge iGEM team members are trained in WHMIS as well as site-specific training in accordance with University of Lethbridge Risk and Safety Services. Training includes an introduction to biosafety basics such as personal protection equipment, aseptic technique, and appropriate disposal of biohazardous materials. Some members have additional training such as radiation and animal care training.</p>
 +
<p class=ex4>c) &nbsp;Please give a link to the laboratory safety training requirements of your institution (college, university, community lab, etc). Or, if you cannot give a link, briefly describe the requirements.</p>
 +
<p class="ex"><a href="http://www.uleth.ca/risk-and-safety-services/content/safety-0">http://www.uleth.ca/risk-and-safety-services/content/safety-0</a></p>
 +
<p>2.<strong>&nbsp;Your Local Rules and Regulations</strong></p>
 +
<p class=ex4>a) &nbsp;Who is responsible for biological safety at your institution? (You might have an Institutional Biosafety Committee, and Office of Environmental Health and Safety, a single Biosafety Officer, or some other arrangement.) Have you discussed your project with them? Describe you concerns they raised, and any changes you made in your project based on your discussion.</p>
 +
<p class="ex">The University of Lethbridge Risk and Safety Services department has appointed a committee for biosafety. This committee ensures that biological materials are used safely on campus. We have discussed our project with them and they forsee no problems with the Lethbridge 2014 iGEM project.&nbsp;</p>
 +
<p class=ex4>b) &nbsp;What are the biosafety guidelines of your institution? Please give a link to these guidelines, or briefly describe them if you cannot give a link.</p>
 +
<p class="ex"><a href="http://www.uleth.ca/risk-and-safety-services/content/biosafety">http://www.uleth.ca/risk-and-safety-services/content/biosafety</a></p>
 +
<p class=ex4>c) &nbsp;In your country, what are the regulations that govern biosafety in research laboratories? Please give a link to these regulations, or briefly describe them if you cannot give a link.</p>
 +
<p class="ex5">The Canadian Biosafety Standards and Guidelines set by the Public Health Agency of Canada.
 +
<br><a href="http://canadianbiosafetystandards.collaboration.gc.ca/">http://canadianbiosafetystandards.collaboration.gc.ca/</a></p>
 +
<p>3.<strong>&nbsp;The Organism and Parts that You Use</strong></p>
 +
<p class="ex"><a href="https://2014.igem.org/File:Lethbridge_Safety2014_Spreadsheet.xls">https://2014.igem.org/File:Lethbridge_Safety2014_Spreadsheet.xls</a></p>
 +
<p>4.<strong>&nbsp;Risks of Your Project Now</strong></p>
 +
<p class=ex4>Please describe risks of working with the biological materials (cells, organisms, DNA, etc.) that you are using in your project. If you are taking any safety precautions (even basic ones, like rubber gloves), that is because your work has some risks, however small. Therefore, please discuss possible risks and what you have done (or might do) to minimize them, instead of simply saying that there are no risks at all.</p>
 +
<p>a) &nbsp;Risks to the safety and health of team members, or other people working in the lab:</p>
 +
<p class="ex">Ethidium bromide (EtBr) used to detect DNA is a potential carcinogen and UV rays are known to cause DNA mutations.&nbsp;Eukaryotic cell cultures, such as human embryonic kidney cells (HEK-293 cells) do pose a cancer risk if handled improperly.</p>
 +
<p>b) &nbsp;Risks to the safety and health of the general public (if any biological materials escaped from your lab):</p>
 +
<p class="ex">EtBr used to detect DNA is a potential carcinogen and UV rays are known to cause DNA mutations.&nbsp;Eukaryotic cell cultures, such as human embryonic kidney cells (HEK-293 cells) do pose a cancer risk if handled improperly. Any enzymes (i.e. restriction and ligase enzymes) and DNA used in the lab are of very minimal risk to the public.</p>
 +
<p>c) &nbsp;Risks to the environment (from waste disposal, or from materials escaping from your lab):</p>
 +
<p class="ex">Minimal risk to the environment as all waste is disposed of using necessary, effective, and widely used safety precautions and disposal methods.</p>
 +
<p class=ex4>d) &nbsp;Risks to security through malicious mis-use by individuals, groups, or countries:</p>
 +
<p class="ex">Minimal risk for malicious mis-use by individuals, groups or countries as our cell lines and parts do not pose a significant threat to the environment or individuals</p>
 +
<p>e) &nbsp;What measures are you taking to reduce these risks? (For example: safe lab practices, choices of which organisms to use.)</p>
-
</body>
+
<p class="ex">Any work performed in the lab is done in a manner that poses minimal risk to team members and other people working in the lab. For instance, proper PPE such as lab coats and gloves are worn when working with EtBr. EtBr-stained gels are analyzed in a contained box that protects the users from UV rays.&nbsp;</p>
-
</html>
+
<p class="ex">The <em>E. coli</em> strains we use are non pathogenic and pose little risk to the general public. Despite this, proper disposal of biohazardous materials are followed - any disposable laboratory materials are autoclaved prior to disposal and any reusable materials are decontaminated with bleach as per standard operating procedures. All eukaryotic cell lines are handled as per biosafety level 2 rules and guidelines and are disposed of correspondingly.</p>
 +
<p>5.<strong>&nbsp;Risks of Your Project in the Future</strong><br /></p>
 +
<p class=ex4>What would happen if all your dreams came true, and your project grew from a small lab study into a commercial/industrial/medical product that was used by many people? We invite you to speculate broadly and discuss possibilities, rather than providing definite answers. Even if the product is &quot;safe&quot;, please discuss possible risks and how they could be addressed, rather than simply saying that there are no risks at all.</p>
 +
<p class=ex4>a) &nbsp;What new risks might arise from your project&#39;s growth? (Consider the categories of risk listed in parts a-d of the previous question: lab workers, the general public, the environment, and malicious mis-uses.) Also, what risks might arise if the knowledge you generate or the methods you develop became widely available?</p>
 +
<p class="ex">In general, the application of our products on mass could yield new risk factors that need to be addressed. Due to the mass production of both E. coli, human, and mouse cell lines needed for research and end-user use, safe and effective guidelines for disposal will need to be followed. Consequently, this may require the development of enhanced disposal methods specific for this purpose. In addition, the knowledge gained if we could specifically target astrocytes with exosomes to deliver a plasmid could be used maliciously - our plasmid DNA could be exchanged for another plasmid containing a harmful gene. On the other hand, the methods and knowledge generated from our project for non-antibiotic selection of bacterial strains would have a positive effect if the information were to become widely available.</p>
 +
<p class=ex4>b) Does your project currently include any design features to reduce risks? Or, if you did all the future work to make your project grow into a popular product, would you plan to design any new features to minimize risks? (For example: auxotrophic chassis, physical containment, etc.) Such features are not required for an iGEM project, but many teams choose to explore them.</p>
 +
<p class="ex">Our system for antibiotic free selection would result in a reduction of the use of antibiotics. As such, its success would result in reducing the risk of antibiotic resistant bacteria.</p>

Latest revision as of 02:51, 18 October 2014


Safety

1. Your Training

a)  Have your team members received any safety training yet?

Yes, we have already received safety training.

b)  Please briefly describe the topics that you learned about (or will learn about) in your safety training.

All University of Lethbridge iGEM team members are trained in WHMIS as well as site-specific training in accordance with University of Lethbridge Risk and Safety Services. Training includes an introduction to biosafety basics such as personal protection equipment, aseptic technique, and appropriate disposal of biohazardous materials. Some members have additional training such as radiation and animal care training.

c)  Please give a link to the laboratory safety training requirements of your institution (college, university, community lab, etc). Or, if you cannot give a link, briefly describe the requirements.

http://www.uleth.ca/risk-and-safety-services/content/safety-0

2. Your Local Rules and Regulations

a)  Who is responsible for biological safety at your institution? (You might have an Institutional Biosafety Committee, and Office of Environmental Health and Safety, a single Biosafety Officer, or some other arrangement.) Have you discussed your project with them? Describe you concerns they raised, and any changes you made in your project based on your discussion.

The University of Lethbridge Risk and Safety Services department has appointed a committee for biosafety. This committee ensures that biological materials are used safely on campus. We have discussed our project with them and they forsee no problems with the Lethbridge 2014 iGEM project. 

b)  What are the biosafety guidelines of your institution? Please give a link to these guidelines, or briefly describe them if you cannot give a link.

http://www.uleth.ca/risk-and-safety-services/content/biosafety

c)  In your country, what are the regulations that govern biosafety in research laboratories? Please give a link to these regulations, or briefly describe them if you cannot give a link.

The Canadian Biosafety Standards and Guidelines set by the Public Health Agency of Canada.
http://canadianbiosafetystandards.collaboration.gc.ca/

3. The Organism and Parts that You Use

https://2014.igem.org/File:Lethbridge_Safety2014_Spreadsheet.xls

4. Risks of Your Project Now

Please describe risks of working with the biological materials (cells, organisms, DNA, etc.) that you are using in your project. If you are taking any safety precautions (even basic ones, like rubber gloves), that is because your work has some risks, however small. Therefore, please discuss possible risks and what you have done (or might do) to minimize them, instead of simply saying that there are no risks at all.

a)  Risks to the safety and health of team members, or other people working in the lab:

Ethidium bromide (EtBr) used to detect DNA is a potential carcinogen and UV rays are known to cause DNA mutations. Eukaryotic cell cultures, such as human embryonic kidney cells (HEK-293 cells) do pose a cancer risk if handled improperly.

b)  Risks to the safety and health of the general public (if any biological materials escaped from your lab):

EtBr used to detect DNA is a potential carcinogen and UV rays are known to cause DNA mutations. Eukaryotic cell cultures, such as human embryonic kidney cells (HEK-293 cells) do pose a cancer risk if handled improperly. Any enzymes (i.e. restriction and ligase enzymes) and DNA used in the lab are of very minimal risk to the public.

c)  Risks to the environment (from waste disposal, or from materials escaping from your lab):

Minimal risk to the environment as all waste is disposed of using necessary, effective, and widely used safety precautions and disposal methods.

d)  Risks to security through malicious mis-use by individuals, groups, or countries:

Minimal risk for malicious mis-use by individuals, groups or countries as our cell lines and parts do not pose a significant threat to the environment or individuals

e)  What measures are you taking to reduce these risks? (For example: safe lab practices, choices of which organisms to use.)

Any work performed in the lab is done in a manner that poses minimal risk to team members and other people working in the lab. For instance, proper PPE such as lab coats and gloves are worn when working with EtBr. EtBr-stained gels are analyzed in a contained box that protects the users from UV rays. 

The E. coli strains we use are non pathogenic and pose little risk to the general public. Despite this, proper disposal of biohazardous materials are followed - any disposable laboratory materials are autoclaved prior to disposal and any reusable materials are decontaminated with bleach as per standard operating procedures. All eukaryotic cell lines are handled as per biosafety level 2 rules and guidelines and are disposed of correspondingly.

5. Risks of Your Project in the Future

What would happen if all your dreams came true, and your project grew from a small lab study into a commercial/industrial/medical product that was used by many people? We invite you to speculate broadly and discuss possibilities, rather than providing definite answers. Even if the product is "safe", please discuss possible risks and how they could be addressed, rather than simply saying that there are no risks at all.

a)  What new risks might arise from your project's growth? (Consider the categories of risk listed in parts a-d of the previous question: lab workers, the general public, the environment, and malicious mis-uses.) Also, what risks might arise if the knowledge you generate or the methods you develop became widely available?

In general, the application of our products on mass could yield new risk factors that need to be addressed. Due to the mass production of both E. coli, human, and mouse cell lines needed for research and end-user use, safe and effective guidelines for disposal will need to be followed. Consequently, this may require the development of enhanced disposal methods specific for this purpose. In addition, the knowledge gained if we could specifically target astrocytes with exosomes to deliver a plasmid could be used maliciously - our plasmid DNA could be exchanged for another plasmid containing a harmful gene. On the other hand, the methods and knowledge generated from our project for non-antibiotic selection of bacterial strains would have a positive effect if the information were to become widely available.

b) Does your project currently include any design features to reduce risks? Or, if you did all the future work to make your project grow into a popular product, would you plan to design any new features to minimize risks? (For example: auxotrophic chassis, physical containment, etc.) Such features are not required for an iGEM project, but many teams choose to explore them.

Our system for antibiotic free selection would result in a reduction of the use of antibiotics. As such, its success would result in reducing the risk of antibiotic resistant bacteria.